Key result
Irbesartan significantly slowed the rate of eGFR decline (-2.34 mL/min/1.73 m2/year) compared to amlodipine (-3.76) and placebo (-3.52) in patients with Type 2 diabetic nephropathy.
Why the study?
Does irbesartan reduce the rate of eGFR decline in patients with established Type 2 diabetic nephropathy and CKD Stages 1-5 compared to amlodipine and placebo?
Population
Patients with established Type 2 diabetic nephropathy and CKD Stages 1-5
Comparison
Irbesartan vs Amlodipine and placebo
Design
Cohort
Follow-up
up to 48 months
Authors
Loading...
Supports irbesartan benefit via eGFR in diabetic nephropathy; hypothesis-generating, needs prospective validation before practice change.
RCT
Does irbesartan reduce the rate of eGFR decline in patients with established Type 2 diabetic nephropathy and CKD Stages 1-5 compared to amlodipine and placebo?
Absolute Event Rate: -2.34% vs -3.52%
p-value: p=<0.0001
Irbesartan significantly slows the rate of eGFR decline in patients with Type 2 diabetic nephropathy compared to amlodipine and placebo, with greater benefit seen with longer treatment duration.
Evans et al. (2011) conducted an RCT in Type 2 diabetic nephropathy and CKD Stages 1-5. Irbesartan vs. Amlodipine and placebo was evaluated on Rate of eGFR decline (mL/min/1.73 m2/year) (p=<0.0001). Irbesartan significantly slowed the rate of eGFR decline (-2.34 mL/min/1.73 m2/year) compared to amlodipine (-3.76) and placebo (-3.52) in patients with Type 2 diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: